Sign In
Buy SONN
$1.26
+0 (+0%)
At Close: Feb 27, 2026
Sonnet BioTherapeutics Announces Pricing of $4.55 Million Underwritten Public Offering
07:30am, Wednesday, 25'th Oct 2023
PRINCETON, NJ / ACCESSWIRE / October 25, 2023 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("we," "us," "our," "Sonnet" or the "Company"), a clinical-stage company developing innovative targe
PRINCETON, NJ / ACCESSWIRE / October 17, 2023 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic dru
Sonnet BioTherapeutics Announces Results of Biodistribution Studies Demonstrating Solid Tumor Targeting Using the FHAB Technology
07:30am, Wednesday, 20'th Sep 2023
Two independent radiolabeling studies showed a 2.5- to 4.7-fold increase in tumor tissue with mIL12-FHAB, the mouse version of SON‑1010, compared with mIL-12 alone Accumulation was observed in tumor
Sonnet BioTherapeutics Regains Nasdaq Minimum Bid Price Compliance
08:30am, Tuesday, 19'th Sep 2023
PRINCETON, NJ / ACCESSWIRE / September 19, 2023 / Sonnet BioTherapeutics Holdings, Inc., (NASDAQ:SONN) a clinical-stage company developing targeted immunotherapeutic drugs, announced today that it has
7 F-Rated Biotech Stocks You Shouldn't Touch With a 10-Foot Pole
07:20am, Friday, 25'th Aug 2023
Investing in biotech stocks can be challenging. The rewards can be great when your company hits on a popular drug, treatment or product.
Sonnet (SONN) Up as Ovarian Cancer Drug Enters Clinical Study
11:01am, Thursday, 17'th Aug 2023
Sonnet (SONN) receives FDA clearance to begin clinical development for its combination therapy of SON-1010 and Roche's atezolizumab, for the potential treatment of platinum-resistant ovarian cancer.
An IND was required to conduct the SB221 study of platinum-resistant ovarian cancer (PROC) with the combination of Sonnet's SON-1010 and Roche's atezolizumab (Tecentriq ® ) in the US As part of the o
Why Is Sonnet BioTherapeutics (SONN) Stock Down 5% Today?
09:23am, Monday, 31'st Jul 2023
Sonnet BioTherapeutics (NASDAQ: SONN ) stock is taking a beating on Monday after the company announced a public stock offering. Investors will note that this public stock offering comes from selling
Sonnet BioTherapeutics to Present at the 2023 BTIG Virtual Biotechnology Conference
09:00am, Monday, 31'st Jul 2023
PRINCETON, NJ / ACCESSWIRE / July 31, 2023 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) ("Sonnet" or the "Company"), a biopharmaceutical company developing innovative targeted biologic drugs,
Best Penny Stocks to Buy Under $1? 10 To Watch Now
10:01am, Thursday, 22'nd Jun 2023
Stocks that are priced below $5 per share are typically referred to as penny stocks. However, for the purpose of this article, we will be focusing specifically on penny stocks that are priced under $1
Best Penny Stocks to Buy Under $1? 7 To Watch Now
12:48pm, Friday, 16'th Jun 2023
Typically, we refer to stocks trading for less than $5 per share, as penny stocks. However, for this article, we're focusing specifically on penny stocks under $1.
Best Penny Stocks to Buy Under $1? 4 To Watch Now
12:43pm, Thursday, 15'th Jun 2023
Ever find yourself daydreaming about striking it rich in the stock market? Well, buckle up, because we're about to dive headfirst into the world of penny stocks under $1.
4 Penny Stocks To Watch Under $5 With Big News This Week
01:41pm, Friday, 26'th May 2023
Everyone is looking for an edge to find penny stocks to buy before the masses. The difficult part of this is that many of these cheap stocks lack liquidity.
3 Hot Penny Stocks To Watch Under $1, Time To Buy?
03:25pm, Thursday, 18'th May 2023
Penny stocks under $1 to watch this week. The post 3 Hot Penny Stocks To Watch Under $1, Time To Buy?
PRINCETON, NJ / ACCESSWIRE / April 17, 2023 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN), a clinical-stage company developing targeted immunotherapeutic drugs, announced today that the compan
